| abstract |
The present invention relates to an antibody against PD-L1 (Programmed death-ligand 1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector containing the nucleic acid, a cell transformed with the vector, the antibody or antigen-binding fragment thereof. It relates to a manufacturing method, a composition for preventing or treating cancer comprising the same, and a composition for combined administration. |